scholarly journals Cleaner Production Quality Regulation Strategy of Pharmaceutical with Collusive Behavior and Patient Feedback

Complexity ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-15
Author(s):  
Junmei Rong ◽  
Lilong Zhu

The quality of pharmaceuticals has always been a hot issue in the world, and it involves public health, economic development of countries, social stability, and national security. Cleaner production is a prerequisite for ensuring the quality of medicines. However, the various types of counterfeit pharmaceuticals and fake vaccines exposed in the recent years have revealed many problems, such as lacking government regulation, loose quality management of companies, illegal profit of medical service agencies, and failure of patient complaints. This paper’s two innovations are as follows: first, it not only considers the collusion between pharmaceutical companies and medical service agencies, but also introduces patient feedback to study drug quality regulation strategies from a microperspective; second, this paper constructs a tripartite evolutionary game model involving cleaner production pharmaceutical companies, medical service agencies, and the governments to analyze the evolutionary stability using the Lyapunov first rule. The results of the research show that, first, improvement of patient complaint rates can effectively curb collusive behavior and promote the stable improvement of cleaner production drug quality; second, the governments must impose sufficient fines on pharmaceutical companies to avoid a stable strategic combination of collusion; third, enhancing patient feedback can speed up the evolution of the stable choice of legitimate strategies by pharmaceutical companies and the medical service agencies; finally, the government reducing the strict regulation costs can increase the strict regulation rate employed in the evolution process and slow down the pace of evolution to loose regulation. In addition, the simulation analysis was carried out using Matlab 2017b, which verified the validity of the model and proved the practical meaning of countermeasures and suggestions for improving government quality regulation.

2019 ◽  
Vol 86 ◽  
pp. 103914
Author(s):  
Éva Németh-Zámboriné ◽  
Péter Rajhárt ◽  
Katarzyna Seidler-Łożykowska ◽  
Zsuzsanna Pluhár ◽  
Krisztina Szabó

2021 ◽  
Author(s):  
◽  
Amy Hill

<p>This paper explores one very important issue in the regulatory regime for medicines in New Zealand and around the world- the deficit of information about medicines available to doctors, patients and independent researchers. Much of the information about safety, efficacy and quality of drugs is held and controlled by pharmaceutical companies and regulators. The public is entitled to this information in full.</p>


Author(s):  
Л.В. Кузнецова ◽  
Л.Ю. Бахтина ◽  
И.Ю. Малышев

В кратком обзоре обсуждаются задачи фармацевтических компаний, и вопросы о наиболее рациональном соотношении скорости, стоимости и качества процесса разработки лекарств и технологий (DDD). Делается заключение, что экспериментальный дизайн и методы медико-фармакологических исследований должны разрабатываться на основании современных принципов и представлений о содержании этапов DDD, с особым акцентом на высокое качество научных исследований на этапе открытия. This brief review discusses challenges of pharmaceutical companies and issues of the most rational relationship between the speed, cost, and quality of the process for drug and technology development (DTD). It was concluded that the experimental design and methods of medical and pharmacological research should be developed on the basis of modern principles and ideas about the essence of DTD stages with a particular emphasis on the high quality of scientific research at the stage of discovery.


2012 ◽  
Vol 15 (2) ◽  
pp. 165-169
Author(s):  
Shibtosh Sarker ◽  
Arindom Pal ◽  
Jesmin Sultana

The purpose of the present study was to investigate whether or not the pharmaceutical companies of Bangladesh are providing all the necessary information and instructions in the packaging materials of pharmaceutical products which are available in Bangladesh. With this aim, the sample of secondary packaging material (cartons, labels, inserts or direction slips) of a total 150 products (from 50 generics) marketed by 15 pharmaceutical companies have been selected and were collected from different medical stores of Dhaka city. The packaging materials of the collected samples were then evaluated based on various regulatory and clinical parameters. It was found that some of the packaging materials of these selected pharmaceutical products lack several  important information in terms of clinical and regulatory parameters which limits the quality of these packaging materials. DOI: http://dx.doi.org/10.3329/bpj.v15i2.12585 Bangladesh Pharmaceutical Journal 15(2): 165-169, 2012


2020 ◽  
Vol 8 (4) ◽  
pp. 524-530
Author(s):  
I.А. Krotov ◽  
◽  
O.E. Konovalov ◽  
◽  

Aim. Analysis of the results of parents' assessment of the conditions of US diagnostics of children. Materials and Methods. Assessment of the conditions for receiving ultrasound examination, based on the results of a questionnaire survey of 424 parents of children who underwent this medical service at the National Medical Research Center of Children's Health of the Ministry of Health of Russia, is presented. Mathematical processing of the obtained data was carried out using the methods of variation statistics and correlation analysis. Results. 83.5% of parents surveyed were satisfied with the ultrasound diagnostic services provided to their children, 12.3% – were satisfied only partially. According to respondents’ opinions, the main reasons for dissatisfaction were insufficient qualification of specialist and low quality of the equipment used. The majority of individuals participating in the survey, considered waiting for ultrasound not long, in 77.6% of cases it was carried out within 1-2 days after the appointment. Ultrasonography in an outpatient clinic and in a hospital was mainly carried out free of charge, as part of compulsory medical insurance – in 86.1 and 87.5% of cases, respectively. Only 14.3% of respondents noted that they had the financial ability to pay for examination of the child from personal funds. It was found that 12.7% of parents had to refuse, for this or that rea-son, from the proposed ultrasound methods of examination of the child. Conclusion. The vast majority of the parents surveyed were satisfied with the ultrasound diagnostics services provided to their child. The main reasons for refusing from ultrasound were a sharply negative reaction of the child, as well as the opinion about the possible harm of the examination and the expected pain from the procedure.


Sign in / Sign up

Export Citation Format

Share Document